Pharmacodynamic Evaluation of Modernized External-Use Traditional Chinese Medicine: A Technical Guid

Pharmacodynamic evaluation of modernized external-use Traditional Chinese Medicine (TCM) provides the scientific evidence required to substantiate efficacy claims for topical herbal formulations such as ointments, plasters, liniments, and gels. By combining validated in vitro assays with GLP-compliant in vivo models, this evaluation framework supports new drug applications, the modernization of classical formulas, and international regulatory acceptance. This guide outlines the sample types, testing items, analytical methods, and practical applications involved in external-use TCM efficacy assessment.

Technical Overview

Pharmacodynamic evaluation, commonly known as efficacy testing, is the systematic study of a product's biological effects, dose-response relationships, and mechanisms of action. For external-use TCM, this discipline addresses topical and transdermal preparations derived from classical prescriptions, compound herbal formulas, or newly developed botanical extracts. As TCM modernization advances, traditional dosage forms are being converted into pharmaceutical-grade products that must demonstrate efficacy through standardized, reproducible, and scientifically defensible testing.

External-use TCM pharmacodynamics presents unique technical challenges compared with oral formulations. Efficacy depends not only on the intrinsic activity of herbal constituents but also on percutaneous absorption, formulation matrix behavior, local tissue exposure, and skin retention. A comprehensive evaluation program therefore integrates pharmacological endpoints with dermal pharmacokinetic characterization to build a complete efficacy profile suitable for regulatory submission.

Core objectives of a modern evaluation program typically include:

• Confirmation of the primary pharmacological action corresponding to the intended clinical indication
• Establishment of dose-effect and exposure-effect relationships, including application frequency and duration
• Comparative benchmarking against approved positive-control drugs and reference formulations
• Generation of data packages aligned with national pharmacopoeia standards and drug registration technical requirements

Testing Samples

Ointments, Creams, and Gels

Semisolid preparations represent the largest category of modernized external-use TCM products. Both single-herb extract formulations and multi-component compound preparations are evaluated as finished dosage forms or as concentrated active extracts, depending on the stage of development. Testing verifies that the semisolid matrix does not interfere with the release and activity of active constituents.

Plasters, Cataplasms, and Transdermal Patches

Traditional plasters have largely been replaced by cataplasms (hydrogel patches) and pressure-sensitive adhesive patches. Evaluation for these dosage forms emphasizes sustained release, skin adhesion performance, percutaneous delivery efficiency, and residual drug content after removal, together with the corresponding in vivo efficacy readouts.

Liniments, Tinctures, and Sprays

Liquid external preparations frequently contain volatile and lipophilic herbal constituents. Pharmacodynamic assessment addresses both immediate effects, such as local cooling and analgesia, and cumulative effects after repeated application, while accounting for solvent evaporation and concentration changes on the skin surface.

Powders, Aerosols, and Wash Preparations

External wash powders, foot bath preparations, and aerosol sprays are evaluated in their reconstituted or delivered form. Study designs consider realistic dilution ratios, contact time, and application methods that reflect actual clinical use conditions.

Testing Items

Testing items are selected according to the intended therapeutic claims and the properties of the herbal ingredients. A standard panel for external-use TCM efficacy assessment includes the following endpoints:

• Anti-inflammatory activity against acute and chronic inflammation models
• Analgesic activity, covering both peripheral and central pain modulation pathways
• Antibacterial and antifungal activity against common skin and wound pathogens
• Wound healing and tissue regeneration, including promotion of granulation and re-epithelialization
• Hemostatic activity and reduction of bleeding time
• Antipruritic (anti-itch) activity in dermatitis and sensitization models
• Antiedema activity in vascular permeability assays
• Burn and scald repair efficacy, including evaluation of scab formation and healing quality
• Local microcirculation improvement and anti-blood-stasis effects
• Percutaneous absorption, skin retention, and release characteristics of active markers

Testing Methods

In Vitro Assays

In vitro methods provide rapid, reproducible screening and mechanistic insight before animal studies are initiated:

• Agar diffusion and broth microdilution assays to determine minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) against organisms such as Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, Candida albicans, and common dermatophytes
• Cell-based assays using human keratinocytes, dermal fibroblasts, and macrophage cell lines to quantify suppression of inflammatory mediators including nitric oxide, prostaglandin E2, tumor necrosis factor-alpha, and interleukin-6
• Franz vertical diffusion cell experiments using excised rat or porcine skin to measure transdermal flux, cumulative permeation, and skin deposition of active markers by HPLC or LC-MS analysis

In Vivo Efficacy Models

Animal models constitute the core evidence for efficacy claims and are conducted under GLP-compliant conditions with ethical committee approval:

• Xylene-induced ear edema in mice and carrageenan-induced rat paw edema for acute anti-inflammatory activity
• Cotton pellet granuloma and granuloma pouch models for chronic proliferative inflammation
• Acetic acid-induced writhing test for peripheral analgesia, and hot plate or tail-flick tests for central analgesic activity
• Excision wound, incision wound, and deep burn models assessing wound contraction rate, healing time, tensile strength, hydroxyproline content, and histopathological scoring of granulation tissue and re-epithelialization
• Mouse tail amputation and liver scratch models for hemostatic efficacy

Study Design and Statistical Standards

All studies follow randomized, blinded, controlled designs incorporating blank control, vehicle or matrix control, positive drug control, and at least three dose levels of the test article. Sample sizes are justified by power analysis, and results are analyzed with appropriate parametric or non-parametric statistical methods. Dose selection for topical administration is derived from human equivalent surface-area conversions, skin tolerance data, and preliminary dose-ranging studies.

Applications

Pharmacodynamic evaluation data serve multiple purposes across the product lifecycle:

• Support for investigational new drug and new drug application dossiers submitted to national regulatory authorities
• Modernization and secondary development of classical formulas, hospital preparations, and legacy products
• Efficacy substantiation for herbal cosmetics, disinfectant products, and medical devices incorporating TCM-derived actives
• Formulation optimization, excipient screening, and comparative efficacy studies between candidate preparations
• Bridging data packages for international market access, where evidence-based dossiers are mandatory
• Post-marketing re-evaluation and quality consistency verification across production batches

FAQ

What is the difference between pharmacodynamic evaluation and safety testing for external-use products?

Pharmacodynamic evaluation demonstrates that a product produces the claimed therapeutic effect, while safety testing, including skin irritation, sensitization, and acute dermal toxicity studies, establishes that the product does not cause harm under intended use conditions. Regulatory submissions for external-use TCM require both components, and they are typically conducted in parallel within the same preclinical program.

How long does a complete efficacy evaluation program take?

A standard program combining in vitro screening and core in vivo models generally requires three to six months, depending on model complexity, wound healing observation periods, and the number of dose groups. Programs involving chronic inflammation models or long-term burn repair assessment may extend to eight months or longer.

Which animal species are most commonly used?

Mice and rats are the primary species for anti-inflammatory, analgesic, hemostatic, and wound healing models because their skin physiology and inflammatory responses are well characterized. Guinea pigs and rabbits are used for specific sensitization and dermal response studies where regulatory guidelines specify them.

How are topical dose levels determined?

Dose levels are established by converting intended human application amounts to animal equivalents based on body surface area, then bracketing the clinical dose with lower and higher levels. Skin coverage capacity, application frequency, and matrix occlusion effects are also factored into the final dose design.

Can the same data support both pharmaceutical and cosmetic claims?

Core efficacy models can often be adapted, but the claim structure differs. Pharmaceutical products require disease-oriented endpoints under drug registration standards, whereas cosmetics require consumer-perceivable effects supported by appropriately designed studies. Testing protocols should be aligned with the target regulatory category from the outset to avoid redundant studies.